United Therapeutics (UTHR) Return on Capital Employed (2010 - 2026)

United Therapeutics has disclosed Return on Capital Employed across 17 years of filings, most recently posting 21.43% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 21.43%, up 89.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 21.43% (up 89.0% YoY), and the FY2025 annual result was 21.14%, up 4.0% from the prior year.
• Return on Capital Employed came in at 21.43% for Q1 2026 at United Therapeutics, up from 21.16% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 21.87% in Q2 2024 to a low of 16.63% in Q1 2023.
• The 5-year median for Return on Capital Employed is 19.84% (2025), against an average of 19.52%.
• Across the five-year window, Return on Capital Employed soared 991 bps in 2022 and plunged 203 bps in 2025, its largest moves.
• United Therapeutics' Return on Capital Employed stood at 17.59% in 2022, then increased by 7 bps to 18.84% in 2023, then grew by 12 bps to 21.17% in 2024, then dropped by 0 bps to 21.16% in 2025, then advanced by 1 bps to 21.43% in 2026.
• The last three Return on Capital Employed figures came in at 21.43% (Q1 2026), 21.16% (Q4 2025), and 21.08% (Q3 2025), per Business Quant data.